4//SEC Filing
Davis Chaim 4
Accession 0001491519-19-000001
CIK 0000896747other
Filed
Jan 24, 7:00 PM ET
Accepted
Jan 25, 2:49 PM ET
Size
10.4 KB
Accession
0001491519-19-000001
Insider Transaction Report
Form 4
Davis Chaim
Director
Transactions
- Award
Common Shares
2019-01-23$0.08/sh+38,993$3,119→ 132,536 total - Other
Non-Statutory Stock Option
2013-04-26$0.18/sh+50,000$9,000→ 50,000 totalExercise: $0.18From: 2014-04-26Exp: 2023-04-26→ Common Shares (50,000 underlying) - Purchase
Common Shares
2019-01-23$0.10/sh+500,000$50,000→ 2,449,915 total(indirect: By Revach Fund, LP)
Footnotes (7)
- [F1]38,993 shares of restricted stock were issued to Davis as compensation for his attendance at a meeting of the Company's Board of Directors held in January 2019. This stock issuance is in accordance with the director compensation structure approved by the Company's Board of Directors on March 22, 2018 (as indicated in the Company's Proxy Statement filed with the Commission on April 20, 2018).
- [F2]The volume weighted average price of the Company's common shares for the 10 days preceding the issuance was $0.0833 per share.
- [F3]These restricted shares of common stock were issued in connection with a private placement of up to 2,000,000 units of common stock as disclosed in a Current Report on Form 8-K filed with the Commission on December 24, 2018. Due to a technical delay, the actual issuance of the shares was not affected until January 25, 2019.
- [F4]The restricted common shares were issued in connection with a private placement completed on December 24, 2018. The Revach Fund, LP was one of the accredited investors who participated in the private placement. 500,000 units were purchased at $0.10 per share; resulting in a total purchase price of $50,000. Davis is a managing member of Revach Group, LLC which operates as the general partner for the Revach Fund,LP. Davis serves as the Chairman of the Board of the Company.
- [F5]The price per unit in the private placement was $0.10 per share.
- [F6]The common shares are in the name of Revach Fund, LP. The reporting person (Davis) is a managing member of Revach Group, LLC which operates as the general partner for the Revach Fund, LP.
- [F7]This non-statutory stock option was previously reported on a Form 3 filed by Davis on April 19, 2018.This stock option is being re-stated on this Form 4. It is not a new award.
Documents
Issuer
AMERICAN BIO MEDICA CORP
CIK 0000896747
Entity typeother
Related Parties
1- filerCIK 0001491519
Filing Metadata
- Form type
- 4
- Filed
- Jan 24, 7:00 PM ET
- Accepted
- Jan 25, 2:49 PM ET
- Size
- 10.4 KB